Prime Medicine (PRME) Common Equity (2021 - 2026)

Prime Medicine (PRME) has 6 years of Common Equity data on file, last reported at $76.7 million in Q1 2026.

• Quarterly Common Equity fell 28.27% year-over-year to $76.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.7 million (down 28.27% YoY) and the FY2025 annual result came in at $120.9 million, down 21.08% from the prior year.
• Common Equity eased to $76.7 million in Q1 2026, from $120.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $316.3 million in Q4 2022 to a low of -$223.1 million in Q3 2022.
• A 5-year average of $111.0 million and a median of $153.1 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 302.42% in 2022, down 136.29% in 2022.
• Tracing PRME's Common Equity over 5 years: stood at $316.3 million in 2022, then slumped by 57.92% to $133.1 million in 2023, then advanced by 15.09% to $153.1 million in 2024, then decreased by 21.08% to $120.9 million in 2025, then slumped by 36.54% to $76.7 million in 2026.
• The last three Common Equity figures came in at $76.7 million (Q1 2026), $120.9 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.